Strekin AG is a Basel, Switzerland–based clinical-stage biopharmaceutical company led by CEO and founder Alexander Bausch. The company’s lead drug candidate is STR001, being developed to treat Sudden Sensorineural Hearing Loss. Preclinical data reported that STR001 effectively protects hearing in animal models by blocking oxidative stress and reducing activation of inflammatory signaling in the cochlea. Strekin closed a CHF2.82M Series A financing to fund clinical and regulatory activities. The company intends to use the proceeds to conclude its ongoing Phase 3 RESTORE trial and to prepare for a European filing. As a clinical-stage firm, its near-term focus is completing the pivotal trial and advancing STR001 toward regulatory submission. Strekin AG is a clinical-stage biopharmaceutical company focused on developing treatments for hearing loss. Its lead candidate, STR001, is a PPARγ agonist that protects ciliated inner ear cells through multiple mechanisms. STR001's therapeutic properties have been extensively investigated in different preclinical models of hearing loss and cochlear hair cell protection. The company raised CHF10m in funding and intends to use the proceeds to conduct an international second clinical trial of STR001 as a potential treatment for acute types of hearing loss. Strekin is advancing STR001 into further clinical testing based on its preclinical data, positioning the program toward potential regulatory milestones.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2019